Tie2 Signaling Enhances Mast Cell Progenitor Adhesion to Vascular Cell Adhesion Molecule-1 (VCAM-1) through α4β1 Integrin

Kazumasa Kanemaru¹, Emiko Noguchi²,5, Takahiro Tokunaga²,7, Kei Nagai¹, Takashi Hiroyama⁶, Yukio Nakamura⁴,6, Satoko Tahara-Hanaoka¹,3,5, Akira Shibuya¹,3,5 *

¹ Department of Immunology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan, ² Department of Medical Genetics, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan, ³ Life Science Center of Tsukuba Advanced Research Alliance (TARA), University of Tsukuba, Tsukuba, Ibaraki, Japan, ⁴ Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan, ⁵ Core Research for Evolutional Science and Technology (AMED-CREST), Tokyo, Japan, ⁶ Cell Engineering Division, RIKEN BioResource Center, Kounodai, Tsukuba, Ibaraki, Japan, ⁷ Department of Otorhinolaryngology Head and Neck Surgery, University of Fukui, Fukui, Japan

* ashibuya@md.tsukuba.ac.jp

Abstract

Mast cell (MC) activation contributes considerably to immune responses, such as host protection and allergy. Cell surface immunoreceptors expressed on MCs play an important role in MC activation. Although various immunoreceptors on MCs have been identified, the regulatory mechanism of MC activation is not fully understood. To understand the regulatory mechanisms of MC activation, we used gene expression analyses of human and mouse MCs to identify a novel immunoreceptor expressed on MCs. We found that Tek, which encodes Tie2, was preferentially expressed in the MCs of both humans and mice. However, Tie2 was not detected on the cell surface of the mouse MCs of the peritoneal cavity, ear skin, or colon lamina propria. In contrast, it was expressed on mouse bone marrow–derived MCs and bone marrow MC progenitors (BM-MCps). Stimulation of Tie2 by its ligand angiopoietin-1 induced tyrosine phosphorylation of Tie2 in MEDMC-BRC6, a mouse embryonic stem cell-derived mast cell line, and enhanced MEDMC-BRC6 adhesion to vascular cell adhesion molecule-1 (VCAM-1) through α4β1 integrin. These results suggest that Tie2 signaling induces α4β1 integrin activation on BM-MCps for adhesion to VCAM-1.

Introduction

Mast cells (MCs) are bone marrow (BM)–derived mononuclear cells, found in various tissues, such as the skin and mucosae, that function as sentinel cells in response to pathogens or other signs of infection [1]. Conversely, MCs are also associated with pathological conditions such as allergy through their production of proteases, vasodilating substances, cytokines, and lipid mediators [2].
Numerous studies have reported that the number of MCs increases at the inflammatory sites of allergic diseases in humans and allergic disease models in mice [3–5], probably as a result of the recruitment of MC progenitors (MCp) to those sites [6–9]. Like other leukocytes, MCp recruitment to peripheral tissues is regulated by integrins expressed on MCps [6,10]. To migrate across vascular endothelial cells (ECs) into peripheral tissues, MCps require the α4β1 and α4β7 integrins on their surface to bind to their ligands, mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and vascular cell adhesion molecule-1 (VCAM-1), on the vascular ECs [7,11–13]. Especially in inflamed tissues, such as lung and skin, MCp binding to VCAM-1 but not to MAdCAM-1 is essential for MCp transmigration [7,12]. However, the role of chemokine receptors on MCps remains obscure [14,15], and the mechanism of integrin activation on MCps is not fully understood.

After recruitment to the inflammatory site, several cell surface receptors promote MC activation to enhance immune responses [16]. The high-affinity Fc receptor for IgE (FcεRI) has a critical role in MC activation [17,18]. In addition, other receptors on MCs, such as Toll-like receptors, cytokine receptors, complement receptors, and purinergic receptors recognize the signs of inflammation and transduce activating signals in MCs [16,19]. To regulate MC activation, the MCs also express inhibitory receptors on their cell surface [20–24]. However, the regulatory mechanisms of MC activation remain incompletely understood.

Furthermore, even though various receptors that are involved in MCp recruitment and MC activation have been identified on the cell surface of MCps and MCs, there are still no effective strategies to regulate these events through modulation of the receptor functions for the treatment of allergic diseases. For these reasons, we sought to identify a novel signal-transducing receptor on MCps or MCs that regulates MCp or MC activation.

Methods

Human samples

Peripheral blood mononuclear cells were isolated from the blood of healthy volunteers. Written informed consents were obtained from the volunteers. This study was approved by the ethical review boards of the University of Tsukuba.

Mice

C57BL/6 mice were purchased from Clea Japan (Tokyo, Japan). All mice used were 8–12-week-old females or males. All animal experiments in this study were carried out humanely after receiving approval from the Animal Ethics Committee of the Laboratory Animal Resource Center, University of Tsukuba, and in accordance with Fundamental Guideline for Proper Conduct of Animal Experiment and Related Activities in Academic Research Institutions under the Jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology.

Cells

Human peripheral blood–derived cultured MCs (PB-MCs) were generated, as described [22]. Human T cells (CD3+), B cells (CD19+), and monocytes (CD14+) were isolated from human peripheral blood mononuclear cells by using a MACS cell separation system (Miltenyi Biotec, Bergisch Gladbach, Germany).

Mouse BM–derived cultured MCs (BMMCs) were generated, as described [25].

Mouse ear skin cells were isolated as previously described [26] with a minor modification. In brief, ear tissue was minced, resuspended in RPMI 1640 medium containing 10% FBS and 400 U/mL collagenase type 2 (Worthington Biochemical Corporation, Lakewood, NJ),
incubated at 37°C for 60 min in an orbital shaker, and passed through nylon wool mesh. Cells were then analyzed by flow cytometry.

Mouse colon lamina propria cells were isolated, as previously described [27] with a minor modification. In brief, colon tissues were opened longitudinally, minced into 5 to 10 mm pieces, and washed extensively with cold PBS. Mucosal pieces were incubated twice with 5 mM EDTA (Sigma-Aldrich, St. Louis, MO) in Hanks’ balanced salt solution (HBSS) (Sigma-Aldrich) for 30 min at 37°C, washed with cold PBS and then incubated for 50 min in HBSS containing 400 U/ml collagenase type 2 and 0.1 mg/mL DNase I (Worthington Biochemical Corporation). Large debris was removed from the cell suspension by passage through nylon wool mesh. Cells were isolated by using Percoll density gradient centrifugation (GE Healthcare Biosciences, Little Chalfont, U.K.), and analyzed by flow cytometry.

The mouse embryonic stem cell-derived mast cell line MEDMC-BRC6 was generated at RIKEN BioResource Center (Tsukuba, Japan) [28].

RNA sequencing (RNA-seq)

Total RNA of human PB-MCs, T cells, B cells, and monocytes were extracted by using an RNeasy Mini kit (Qiagen, Hilden, Germany), and a Ribo-Zero rRNA Removal Kit (Illumina, San Diego, CA) was used to remove ribosomal RNA. RNA-seq was performed according to the protocol described in the SOLiD Total RNA-Seq Kit (Life Technologies, Carlsbad, CA). The library was subjected to emulsion PCR (SOLiD™ EZ Bead™ Emulsifier kit, Life Technologies) to generate clonal DNA fragments on beads, followed by bead enrichment (SOLiD™ EZ Bead™ Enrichment kit, Life Technologies). Enriched template beads were sequenced on a SOLiD 5500xl sequencer as single-end, 75-bp reads (Life Technologies). The SOLiD 5500xl output reads were aligned against the human genome reference sequence (hg19) by using LifeScope version 2.5.1 (Life Technologies) to generate BAM files, and subsequent data analysis was performed in Avadis NGS (Strand Scientific Intelligence Inc., San Francisco, CA). The RNA-seq dataset generated in this study was deposited in NCBI’s Gene Expression Omnibus under the accession number GSE71247.

Gene data analyses

To select genes encoding immunoglobulin (Ig)-like receptors or C-type lectin/C-type lectin-like (CLECT) receptors, and immunoreceptors containing signaling motif sequences or catalytic domains in their intracellular portion, we analyzed the predicted amino acid sequences of genes expressed in human PB-MCs by using the NCBI conserved domain database [29] and in-house Perl scripts. The amino acid sequences of signaling motifs are shown in S1 Table. To analyze gene expression in mouse MCs, we used the microarray data (GSE10246). Gene expression values in MCs were defined as the maximum value of the MC samples in GSE10246. The sample names in GSE10246 are shown in S2 Table.

To analyze the extent of specific gene expression in human MCs, data from our RNA-seq analysis were used. The extent of specific gene expression was calculated as the average of each fold change (FC) in gene expression between the MCs and the other cell types (T cells, B cells, and monocytes).

To analyze the extent of specific gene expression in mouse MCs, data from GSE10246 were used. Gene expression for each cell type was defined as the maximum value of the samples of each cell type (S2 Table). The extent of specific gene expression in mouse MCs was calculated in the same manner as for the human data.
Antibodies

Phycoerythrin (PE)/cyanine (Cy) 7-conjugated anti-human c-Kit (104D2) monoclonal antibody (mAb), allophycocyanin (APC)/Cy7-conjugated anti-mouse CD8α (53–6.7), CD11b (M1/70), and B220 (RA3-6B2) mAbs, APC/H7-conjugated anti-mouse CD4 (GK1.5) mAb, BD Horizon V450-conjugated anti-mouse Gr-1 (RB6-8C5) mAb, Pacific blue-conjugated anti-mouse CD3e (500A2) mAb, biotin-conjugated anti-mouse CD4 (GK1.5), CD8α (53–6.7), CD11b (M1/70), B220 (RA3-6B2), and TCRβ (H57-597) mAbs, unconjugated anti-β1 integrin (Ha2/5 and 9EG7) mAbs, and fluorescein-conjugated streptavidin were purchased from BD Biosciences (San Jose, CA). Fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD27 (LG.3A10) and Sca-1 (D7) mAbs, PE-conjugated anti-human Tie2 (33.1) and anti-mouse β7 integrin (FIB27) mAb, PE/Cy7-conjugated anti-mouse c-Kit (2B8) mAb, APC-conjugated anti-mouse ST2 (D1H9) mAb, PerCP/Cy5.5-conjugated anti-mouse β7 integrin (FIB27) mAb, biotin-conjugated anti-mouse TER-119 (TER-119) and Tie2 (TEK4) mAbs, and unconjugated anti-β7 integrin (FIB27) mAb were purchased from BioLegend (San Diego, CA). FITC-conjugated anti-mouse FcεRIα (MAR-1) mAb, and biotin-conjugated anti-mouse FcεRIα (MAR-1) mAb were purchased from eBioscience (San Diego, CA). Biotin-conjugated anti-mouse FcεRIα (MAR-1) mAb was purchased from Beckman Coulter (Pasadena, CA). Horseradish peroxidase (HRP)–conjugated anti-phosphotyrosine (pTyr) Ab (4G10 platinum) was purchased from Merck Millipore (Darmstadt, Germany). Unconjugated anti-Flag (M2) mAb and anti-Flag polyclonal Ab were purchased from Sigma-Aldrich. HRP-conjugated anti rabbit IgG Ab was purchased from GE Healthcare Biosciences.

Flow cytometry

Flow cytometric analyses and cell sorting were performed by using FACS LSRFortessa and FACS Aria flow cytometers (BD Biosciences), respectively. FlowJo software (Tree Star, Ashland, OR) was used for data analyses. Dead cells were stained and excluded by using Propidium iodide solution (P4864, Sigma-Aldrich) or Zombie Violet Fixable Viability Kit (423114, BioLegend).

Isolation of mouse BM-MCp

Mouse BM-MCps were isolated, as previously described [30]. For analyses of Tie2 expression on BM-MCps, BM cells were stained with anti-lineage mAb cocktail (including Pacific blue-conjugated anti-CD3 mAb, BD Horizon V450-conjugated anti-Gr-1 mAb, and APC/Cy7-conjugated anti-CD4, CD8, CD11b, and B220 mAbs), PE/Cy7-conjugated anti-c-Kit mAb, FITC-conjugated anti-FcεRIα, CD27, and Sca-1 mAbs, PerCP/Cy5.5-conjugated anti-β7 integrin mAb, and APC-conjugated anti-ST2 mAb. Tie2 expression on BM-MCps was analyzed by flow cytometry (FACS LSRFortessa flow cytometer, BD Biosciences) with biotin-conjugated anti-Tie2 mAb, followed by PE-conjugated streptavidin.

For BM-MCp isolation, BM cells were stained with biotin-conjugated mAbs specific for lineage markers: TCRβ, CD4, CD8, B220, CD11b, Gr-1, and TER-119. Cells were then incubated with Streptavidin-Particle Plus-DM (BD biosciences). Lineage positive cells were removed by BD IMagnet (BD biosciences). The remaining cells were stained with FITC-conjugated anti-Sca-1 and CD27 mAbs, PE-conjugated anti-β7 integrin mAb, PE/Cy7-conjugated anti-c-Kit mAb, APC-conjugated anti-ST2 mAb, and biotin-conjugated mAbs (anti-TCRβ, CD4, CD8, B220, CD11b, Gr-1, and TER-119) specific to lineage markers and biotin-conjugated anti-FcεRIα mAb, followed by APC/Cy7-conjugated streptavidin. BM-MCps (lineage– c-Kit+ FcεRIα– Sca-1− CD27− β7 integrin− ST2+) were sorted by flow cytometry (FACS Aria flow cytometer, BD Biosciences).
Complementary DNA synthesis and real-time (RT)-PCR

Total RNA was extracted with Isogen reagent (Nippon Gene, Tokyo, Japan), and cDNA was synthesized by using a High Capacity RNA-to-cDNA Kit (Applied Biosystems, Carlsbad, CA). Tek expression was measured with quantitative RT-PCR, performed with SYBR Green master mix (Applied Biosystems) and the specific primers. The Gapdh expression level was used as an internal control to normalize data. Primer sequences of the target genes are: Tek, forward, 5'-GTG AAGGTCGAGTTCGAGGA-3', reverse, 5'-CCCTGTCCACGGTCATAGTT-3'; Gapdh, forward, 5'-TGGTGAAGGGTCGGTGTAAC-3', reverse, 5'-ATGAAGGGGTGTTGATGGC-3'.

Establishment of transfectants

MEDMC-BRC6 transfectants stably expressing wild-type (WT) Tie2 or mutant Tie2 lacking the cytoplasmic portion (ΔCyt) and tagged with a Flag at the N-terminus were established as previously described [25], by transfection with WT Tek cDNA and mutated Tek cDNA encoding the extracellular and transmembrane portions subcloned into the pMXs retroviral vector [31].

Biochemical analysis

To analyze the tyrosine phosphorylation of Tie2, MEDMC-BRC6 transfectants were stimulated with recombinant human angiopoietin-1 (Ang1) (923-AN; R&D Systems, Minneapolis, MN) (250 ng/mL) for 3 to 10 min at 37°C, lysed with 1% NP-40 lysis buffer, and immunoprecipitated with an anti-Flag M2 mAb (F3165; Sigma-Aldrich). Immunoprecipitates were resolved by SDS-PAGE, transferred onto polyvinylidene difluoride membranes by electroblotting, immunblotted with HRP-conjugated anti-pTyr Ab (4G10 and PY20; Merck Millipore) and an anti-Flag polyclonal Ab, followed by an HRP-conjugated anti-rabbit IgG Ab. Proteins were detected by enhanced chemiluminescence (Thermo Fisher Scientific, Waltham, MA).

Adhesion assay

MEDMC-BRC6 transfectants (3 × 10^4 per well), mouse BM-MCs (5 × 10^3 to 1 × 10^4 per well), or mouse BMMCs (3 × 10^4 per well) were incubated in the presence or absence of recombinant human Ang1 (923-AN; R&D Systems) (250 ng/mL) with or without a neutralizing anti-β1 integrin mAb (Ha2/5) (20 μg/mL), a neutralizing anti-β7 integrin mAb (FIB27) (20 μg/mL), or a control Ab (hamster IgM, rat IgG2a) (20 μg/mL) for 30 min to 1 h. Cells were then cultured for 1 h in flat-bottomed 96-well plates that were precoated with a human IgG1 Ab (AG502; Merck Millipore) or mouse VCAM-1-Fc (643-VM; R&D Systems) (3 μg/mL) for 16 h and blocked for 1 h with PBS containing 2% BSA. After removal of the non-adherent cells by gentle washing with PBS, the number of adherent cells in 20 mm^2 per well was counted under a BZ-X710 All-in One Fluorescence Microscope (Keyence, Osaka, Japan).

Statistical analysis

Statistical analyses were performed by using the two-tailed Student's t-test (GraphPad Prism 5, GraphPad Software, La Jolla, CA) for quantitative RT-PCR assay or the ANOVA test with the post-hoc Tukey-Kramer test (GraphPad Prism 5, GraphPad Software) for adhesion assays.
Results

Identification of Tek expression in MCs

To identify a novel receptor that regulates MC activation, we performed RNA-seq analysis of human MCs, which were induced by culture of CD34+ hematopoietic stem cells (HSC) in peripheral blood [22,32]. Human peripheral blood-derived MCs (PB-MCs) were found to express 16,869 genes. By using the NCBI conserved domain database [29] to analyze the predicted amino acid sequences, we selected 383 and 59 genes encoding proteins that belong to the Ig-like receptor superfamily and the CLECT receptor family, respectively (Fig 1A). We then used in-house Perl scripts and the NCBI conserved domain database to select genes encoding receptors that potentially mediated activating or inhibitory signals through the amino acid sequences (S1 Table) of following signaling motifs or catalytic domains in their intracellular regions: immunoreceptor tyrosine-based activation motif (ITAM), immunoreceptor tyrosine-based inhibitory motif (ITIM) or ITIM-like amino acid sequences, PI3K binding motif, or conserved catalytic domains of protein tyrosine kinases (PTKc) and protein tyrosine phosphatase (PTPc) (Fig 1A, S3 Table). Next, we examined the gene expression levels of the candidates in mouse MCs by using the published microarray data (GSE10246) based on BMMC analysis, and selected genes with a normalized expression level of more than 100 (Fig 1A, S3 Table). Finally, to select genes preferentially expressed in MCs compared with other cell types, we analyzed the extent of specific expression in MCs by using the RNA-seq data from human cells and the data from GSE10246 (Fig 1B). On the basis of our results, we focused on
the Tie2-encoding gene *Tek*, which was expressed at higher levels in human and mouse MCs compared with other cell types.

**Tie2 is expressed on BMMCs and BM-MCps in mice and PB-MCs in humans**

Next, we analyzed Tie2 expression on the cell surface of mouse MCs. Although BMMCs expressed Tie2 on the cell surface (Fig 2A), Tie2 was not expressed on MCs in the peritoneal cavity, ear skin, or colon lamina propria (Fig 2B). Since BMMCs are considered immature compared with tissue-resident MCs, on the basis of their granule contents [33,34], we hypothesized that MCps in the bone marrow (BM-MCps) might also express Tie2. As predicted, Tie2 was expressed on BM lineage− c-Kit+ FcεRIα− CD27− β7 integrin+ ST2+ cells (Fig 2C) that has been defined as BM-MCp population [30]. In addition, *Tek* expression was detected in sorted BM-MCps, and it was significantly higher than that in sorted MCs of peritoneal cavity.
We found that Tie2 was also expressed on human PB-MCs, which were characterized by c-Kit+ cells after the culture of CD34+ HSCs in the presence of SCF, IL-6, and IL-3 [22,32] (Fig 2E).

Tie2 signaling enhances MEDMC-BRC6 cell adhesion to VCAM-1 through α4β1 integrin

To study the function of Tie2 on MCps, we established MEDMC-BRC6 transfectants, which express either WT Tie2 (WT/MEDMC-BRC6) or Tie2 lacking the cytoplasmic portion (ΔCyt/MEDMC-BRC6). Cell surface expression of Tie2 was comparable between WT/MEDMC-BRC6 and ΔCyt/MEDMC-BRC6 (S1 Fig). After treatment of the transfectants with angiopoietin-1 (Ang1), which is an agonistic ligand of Tie2 [35], tyrosine phosphorylation of Tie2 was upregulated in WT/MEDMC-BRC6, but not in ΔCyt/MEDMC-BRC6 (Fig 3A). These results indicate that Ang1 induces Tie2 signaling in MEDMC-BRC6.

In inflammatory conditions such as allergic diseases, MCps migrate across vascular ECs into the inflamed tissue via the interaction of α4β1 and α4β7 integrins on MCps with VCAM1 on ECs [7,11,12]. Yet, Ang1-Tie2 signaling enhances cell adhesion to extracellular matrix via β1 integrin [36–38]. In addition, since Ang1 is expressed by peri-endothelial mural cells [39], we hypothesized that Ang1-Tie2 signaling in MCps may participate in MCp migration across vascular ECs by regulating MCp adhesion to VCAM-1 via α4β1 integrin. To test this hypothesis, we treated WT/MEDMC-BRC6 and ΔCyt/MEDMC-BRC6 with Ang1, both of which expressed α4 integrin and β1 integrin (S1 Fig), and examined the adhesion of these cells to plate-coated VCAM-1. We found that treatment with Ang1 enhanced MEDMC-BRC6 adhesion to VCAM-1, which required the cytoplasmic portion of Tie2 (Fig 3B). We then assessed the involvement of α4β1 integrin in this enhancement of adhesion. The addition of a neutralizing Ab against β1 integrin into this assay completely abolished the effect of Ang1-Tie2 signaling on MEDMC-BRC6 adhesion to VCAM-1 (Fig 3C). These results indicate that Tie2 signaling is involved in α4β1 integrin-mediated adhesion of MEDMC-BRC6 to VCAM-1.

We used two clones of anti-β1 integrin mAb (clone Ha2/5 and 9EG7) to analyze the β1 integrin expression on the transfectants (S1 Fig). Clone Ha2/5 recognizes both active and inactive form of β1 integrin, and clone 9EG7 recognizes an activation-associated epitope of β1 integrin. The binding of clone 9EG7 was downregulated in ΔCyt/MEDMC-BRC6 compared with WT/MEDMC-BRC6 (S1 Fig). In contrast, the downregulation of the binding of clone Ha2/5 in ΔCyt/MEDMC-BRC6 was markedly less, compared with that of clone 9EG7 (S1 Fig). These results indicate that the difference of clone 9EG7 binding between WT and ΔCyt/MEDMC-BRC6 was due to less active form of β1 integrin on ΔCyt/MEDMC-BRC6.

Ang1 treatment enhances mouse BM-MCp adhesion to VCAM-1 through α4β1 integrin

To examine whether Tie2 expressed on MCps regulates adhesion of MCps to VCAM-1, we sorted mouse BM-MCps from BM by means of flow cytometry. Similarly to MEDMC-BRC6 transfectant, while BM-MCps showed enhanced adhesion to plate-coated VCAM-1 after treatment with Ang1 (Fig 4A), the Ang1-induced enhancement of BM-MCp adhesion to VCAM-1 was completely abolished in the presence of a neutralizing Ab against β1 integrin (Fig 4B). These results indicate that Tie2 signaling is involved in the α4β1 integrin-mediated adhesion of MCps to VCAM-1.

It is reported that Ang1-Tie2 signaling enhances β1 integrin expression in HSCs and neoplastic glial cells [37,38]. To examine whether Ang1 treatment enhances β1 integrin expression or activation in MEDMC-BRC6 transfectants and BM-MCps, we used two clones of anti-β1
integrin mAbs (Ha2/5 and 9EG7) as described at the previous sub-section. As a result, binding of both mAbs against β1 integrin to MEDMC-BRC6 transfectants and BM-MCs were not enhanced after Ang1 treatment (S2 Fig). These results indicate that Ang1 treatment did not upregulate the expression of β1 integrin on the cell surface.

Unlike the adhesion of MEDMC-BRC6 transfectants, BM-MCp adhesion to VCAM-1 was not inhibited so extensively by adding a neutralizing Ab against β1 integrin. Since α4β7 integrin mAbs (Ha2/5 and 9EG7) as described at the previous sub-section. As a result, binding of both mAbs against β1 integrin to MEDMC-BRC6 transfectants and BM-MCs were not enhanced after Ang1 treatment (S2 Fig). These results indicate that Ang1 treatment did not upregulate the expression of β1 integrin on the cell surface.

Unlike the adhesion of MEDMC-BRC6 transfectants, BM-MCp adhesion to VCAM-1 was not inhibited so extensively by adding a neutralizing Ab against β1 integrin. Since α4β7
integrin is also involved in VCAM-1 dependent MCp transmigration to peripheral tissue [7], we examined the involvement of β7 integrin in BM-MCp adhesion to VCAM-1 by adding a neutralizing anti-β7 integrin Ab into the adhesion assay. As a result, adding both anti-β1 integrin and anti-β7 integrin Abs inhibited BM-MCp adhesion to VCAM-1 greater than adding each of the Ab (S3 Fig). However, even in the condition that both neutralizing mAbs were added, BM-MCp adhesion to VCAM-1 was not inhibited completely. This result indicates that adhesion through integrins other than β1 and β7 integrin or other mechanisms are also involved in the BM-MCp adhesion to VCAM-1.

**Ang1 treatment enhances mouse BMMC adhesion to VCAM-1 through α4β1 and α4β7 integrin**

To examine whether Ang1 treatment activate α4β7 integrin as well as α4β1 integrin for adhesion to VCAM1, we used mouse BMMCs, which, unlike MEDMC-BRC6 transfectants, expressed β7 integrin as well as β1 integrin (S1 and S4A Figs). Ang1 treatment enhanced BMMC adhesion to VCAM-1 (S4B Fig), and this effect was completely abolished by addition of a neutralizing Ab against β1 integrin (S4C Fig). However, addition of a neutralizing Ab...
against β7 integrin also significantly suppressed the effect of Ang1 treatment on the BMMC adhesion (S4D Fig). These results indicate that, although β1 integrin play a major role in BMMC adhesion to VCAM-1, β7 integrin is also involved in the adhesion induced by Ang1.

**Discussion**

Tie2, a receptor-type tyrosine kinase, is expressed on vascular and lymphatic ECs, HSCs, and tumor-associated monocytes [39–41]. Ligands of Tie2 include Ang1 and angiopoietin-2 (Ang2) [39]. There is evidence that in both ECs and HSCs Ang1-Tie2 signaling promotes cell survival, migration, and cell adhesion to extracellular matrix such as fibronectin and collagen via integrin [36,39,42]. Although we found that Tek was preferentially expressed in MCs, it has remained unclear whether Tie2 is expressed on the cell surface of primary MCs and, if it is, what its functional role might be in MC activation.

We showed that although mouse BMMCs expressed Tie2, matured MCs in the mouse peripheral tissues did not (Fig 2A and 2B). The reason for this difference may be that the gene expression data from the human and mouse MCs used for the selection of Tie2 were obtained from in vitro differentiated MCs. In primary cells, we detected Tie2 expression on mouse BM-MCPs in both protein and mRNA levels (Fig 3C and 3D). These results suggest that Tie2 expression on the cell surface is restricted to immature MCs and is suppressed after maturation. We found that Tie2 was also expressed on human PB-MCs (Fig 2E), which are immature MCs, consistent with the case of mouse immature MCs. In addition, lower expressions of Tek in mouse matured tissue MCs compared with the expression in hematopoietic progenitor cells can be also observed in the gene expression database (https://www.immgen.org).

We found that stimulation of Tie2 with Ang1 enhanced adhesion of MEDMC-BRC6 transfectants and mouse BM-MCPs to VCAM-1 via α4β1 integrin (Figs 3 and 4). These results are consistent with previous reports that Ang1-Tie2 signaling enhances adhesion of HSCs and neoplastic glial cells to extracellular matrix via β1 integrin [36–38]. Moreover, there have been reports that the concentration of Ang1 is increased in the serum and lungs of patients with asthma [43,44]. These reports suggest that serum Ang1 may stimulate MCps to enhance their migration across vascular ECs into inflamed tissues. However, this concept is controversial, because another study reported a decrease, rather than an increase, in the serum titer of Ang1 in asthmatic patients [45]. The expression of Ang2, another ligand of Tie2, had also been reported to increase in asthmatic lung [43]. Ang2 is classically known to antagonize the Ang1-Tie2 interaction and to promote EC destabilization at the inflammatory site [46], whereas higher concentration of Ang2 have agonistic effects on Tie2 signaling and enhance EC survival [47,48]. Although further analyses are required, the role of the angiopoietin-Tie2 system in MCp transmigration is a promising target for the treatment of allergic diseases, by regulating the recruitment of MCps to inflamed tissues and preventing the increase in MC numbers at the site of inflammation.

The smaller effect of Ang1 treatment on BM-MCP adhesion to VCAM-1 may be due to a lower expression level of Tie-2 compared to WT/MEDMC-BRC6 transfectant. In addition, it may also be caused by the presence of Ang1 produced by stromal cells, including osteoblasts, and hematopoietic progenitor cells, in the BM [49,50], which had partially activated Tie2 on BM-MCPs in the BM before isolation.

The expression of β1 integrin and the activation-associated epitope of β1 integrin that is recognized by clone 9EG7 were not enhanced by Ang1 treatment (S2 Fig). Since clone 9EG7 can recognize α4β1 integrin in the absence of the ligands [51,52], it may be possible that Ang1-Tie2 signaling enhances the transformation of α4β1 integrin from intermediate affinity form to high affinity form by promoting outside-in signaling after the interaction with VCAM-1.
Although Ang1 treatment of WT/MEDMC-BRC6 increased tyrosine phosphorylation of Tie2 and adhesion to VCAM-1, both tyrosine phosphorylation and adhesion were also detected even before the treatment at a lower level (Fig 3A and 3B). In addition, less active form of β1 integrin was expressed on ΔCyt/MEDMC-BRC6 than on WT/MEDMC-BRC6 (S1 Fig). These results may be caused by ligand-independent Tie2 dimerization in WT/MEDMC-BRC6, as reported in HEK293T transfectant expressing Tie2 showing tyrosine phosphorylation of Tie2 without any stimulation [53].

Ang-1 is also known to regulate HSC quiescence in BM hematopoietic niches [37]. In addition, hematopoietic stem and progenitor cells are retained in BM hematopoietic niches through the interaction between α4β1 integrin expressed on their surface and VCAM-1 present on cells that comprise the niches [54–56]. Thus, our data suggest that Ang-1 may also regulate BM-MCp retention in BM hematopoietic niches via Tie2 signaling.

To analyze Tie2 function more definitively in primary cells, Tie2-deficient cells are required. However, since Tie2-deficient mice die between E10.5 and E12.5 [39], we could not analyze the function of Tie2 using Tie2-deficient BM-MCps. The establishment of MCp-specific Tie2-deficient mice will foster more precise analysis of Tie2 function in MCps.

Supporting Information

S1 Fig. Tie2 and Integrin expressions on MEDMC-BRC6 transfectants. The numbers indicate ratios of mean fluorescence intensity (MFI) of anti-Tie2 mAb or anti-integrin mAb staining to that of isotype control Ab staining.

(TIF)

S2 Fig. β1 integrin expressions after Ang1 treatment. MEDMC-BRC6 transfectants and mouse BM-MCps were incubated in the presence or absence of Ang1 (250 ng/mL) for 90 to 120 min. β1 integrin expressions were then analyzed by flow cytometry. Histograms of solid lines show staining of anti-β1 integrin mAbs to cells incubated with (red) and without (black) Ang1. Shaded histograms show staining of isotype control Abs to cells incubated without Ang1.

(TIF)

S3 Fig. Involvement of β1 and β7 integrins in mouse BM-MCp adhesion to VCAM-1. Mouse BM-MCps were cultured with neutralizing anti-integrin Abs or control Abs (20 μg/mL each) in wells that were precoated with human IgG1 Ab or mouse VCAM-1-Fc. Adherent cells were counted by using a microscope (20 mm² per well).

(TIF)

S4 Fig. Ang1 treatment enhances mouse BMMC adhesion to VCAM-1 through α4β1 and α4β7 integrin. (A) β1 and β7 integrin expressions on BMMCs were analyzed by flow cytometry. (B) Mouse BMMCs were treated with or without Ang1 (250 ng/mL) and cultured in wells that were precoated with human IgG1 Ab or mouse VCAM-1-Fc. Adherent cells, as observed blue-colored, were counted by using a microscope (20 mm² per well). (C) Neutralizing anti-β1 integrin Ab (20 μg/mL) or control Ab (20 μg/mL) was added under the conditions described in B. BMMCs were incubated on VCAM-1-Fc-coated wells, and adherent cells were similarly counted. (D) Neutralizing anti-β7 integrin Ab (20 μg/mL) or control Ab (20 μg/mL) was added under the conditions described in B. BMMCs were incubated on VCAM-1-Fc-coated wells, and adherent cells were similarly counted. Scale bars, 200 μm. Data show mean values ± SEM (n = 4 or 5). *p < 0.05, ***p < 0.001.

(TIF)
S1 Table. Signaling motif sequences.
(XLSX)

S2 Table. Sample names of each cell type in GSE10246.
(XLSX)

S3 Table. Candidate genes in Fig 1A. The genes highlighted were expressed at more than 100 in mouse MCs (GSE10246).
(XLSX)

Acknowledgments
We thank S. Mitsuishi and Y. Nomura for secretarial assistance.

Author Contributions
Conceived and designed the experiments: KK EN ST-H AS. Performed the experiments: KK TT KN. Analyzed the data: KK EN ST-H AS. Contributed reagents/materials/analysis tools: EN TT KN TH YN. Wrote the paper: KK AS.

References
1. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol. 2010; 10: 440–452. doi: 10.1038/nri2782 PMID: 20498670
2. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008; 454: 445–454. doi: 10.1038/nature07204 PMID: 18650915
3. Brightling CE, Bradding P, Symon F a, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med. 2002; 346: 1699–1705. doi: 10.1056/NEJMoa012705 PMID: 12037149
4. Yu M, Tsai M, Tam S, Jones C, Zehnder J, Galli SJ. Mast cells can promote the development of multiple features of chronic asthma in mice. J Clin Invest. 2006; 116: 1633–1641. doi: 10.1172/JCI25702DS1 PMID: 16710480
5. Dahlin JS, Feinstein R, Cui Y, Heyman B, Hallgren J. CD11c+ cells are required for antigen-induced increase of mast cells in the lung. J Immunol. 2012; 189: 3869–3877. doi: 10.4049/jimmunol.1201200 PMID: 22972929
6. Dahlin JS, Hallgren J. Mast cell progenitors: Origin, development and migration to tissues. Mol Immunol. 2015; 63: 9–17. doi: 10.1016/j.molimm.2014.01.018 PMID: 24598075
7. Abonia JP, Hallgren J, Jones T, Shi T, Xu Y, Koni P, et al. Alpha-4 integrins and VCAM-1, but not MAdCAM-1, are essential for recruitment of mast cell progenitors to the inflamed lung. Blood. 2006; 108: 1588–1594. doi: 10.1182/blood-2005-12-012761 PMID: 16670268
8. Pennock JL, Grencis RK. In vivo exit of c-kit+/CD49d(hi)/beta7+ mucosal mast cell precursors from the bone marrow following infection with the intestinal nematode Trichinella spiralis. Blood. 2004; 103: 2655–2660. doi: 10.1182/blood-2003-09-3146 PMID: 14604954
9. Dahlin JS, Ivanson MA, Heyman B, Hallgren J. IgE immune complexes stimulate an increase in lung mast cell progenitors in a mouse model of allergic airway inflammation. PLoS One. 2011; 6: e20261. doi: 10.1371/journal.pone.0020261 PMID: 21625525
10. Gurish MF, Austen KF. Developmental Origin and Functional Specialization of Mast Cell Subsets. Immunity. 2012; 37: 25–33. doi: 10.1016/j.immuni.2012.07.003 PMID: 22840841
11. Boyce J a. Human mast cell progenitors use alpha 4-integrin, VCAM-1, and PSGL-1 E-selectin for adhesive interactions with human vascular endothelium under flow conditions. Blood. 2002; 99: 2890–2896. doi: 10.1182/blood.V99.8.2890 PMID: 11929779
12. Collmann E, Bohnacker T, Marone R, Dawson J, Rehberg M, Stringer R, et al. Transient targeting of phosphoinositide 3-kinase acts as a roadblock in mast cells’ route to allergy. J Allergy Clin Immunol. 2013; 132: 959–968. doi: 10.1016/j.jaci.2013.03.006 PMID: 23683469
13. Gurish MF, Tao H, Abonia JP, Arya A, Friend DS, Parker CM, et al. Intestinal mast cell progenitors require CD49dbeta7 (alpha4beta7 integrin) for tissue-specific homing. J Exp Med. 2001; 194: 1243–1252. doi: 10.1084/jem.194.9.1243 PMID: 11695590
14. Hallgren J, Jones TG, Abonia JP, Xing W, Humbles A, Austen KF, et al. Pulmonary CXCR2 regulates VCAM-1 and antigen-induced recruitment of mast cell progenitors. Proc Natl Acad Sci U S A. 2007; 104: 20478–20483. doi: 10.1073/pnas.0709651104 PMID: 18077323

15. Collington SJ, Hallgren J, Pease JE, Jones TG, Rollins BJ, Westwick J, et al. The role of the CCL2/CCR2 axis in mouse mast cell migration in vitro and in vivo. J Immunol. 2010; 184: 6114–6123. doi: 10.4049/jimmunol.0904177 PMID: 20427772

16. Migalovich-Sheikhet H, Friedman S, Mankuta D, Levi-Schaffer F. Novel identified receptors on mast cells. Front Immunol. 2012; 3: 238. doi: 10.3389/fimmu.2012.00238 PMID: 22876248

17. Dombrowicz D, Flamand V, Brigman KK, Koller BH, Kinet JP. Abolition of anaphylaxis by targeted disruption of the high affinity immunoglobulin E receptor alpha chain gene. Cell. 1993; 75: 969–976. PMID: 8252632

18. Kraft S, Kinet J-P. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol. 2007; 7: 365–378. doi: 10.1038/nri2072 PMID: 17438574

19. Kurashima Y, Amiya T, Nochi T, Fujisawa K, Haraguchi T, Iba H, et al. Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 putoceptors. Nat Commun. 2012; 3: 1034. doi: 10.1038/ncomms2023 PMID: 22948816

20. Shik D, Munitz A. Regulation of allergic inflammatory responses by inhibitory receptors. Clin Exp Allergy. 2010; 40: 700–709. doi: 10.1111/j.1365-2222.2010.03501.x PMID: 20447082

21. Hitomi K, Tahara-Hanaoka S, Someya S, Fujiki A, Tada H, Sugiyama T, et al. An immunoglobulin-like receptor, Allergin-1, inhibits immunoglobulin E-mediated immediate hypersensitivity reactions. Nat Immunol. 2010; 11: 601–607. doi: 10.1038/ni.1886 PMID: 20526344

22. Nagai K, Tahara-Hanaoka S, Morishima Y, Tokunaga T, Imoto Y, Noguchi E, et al. Expression and Function of Allergin-1 on Human Primary Mast Cells. PLoS One. 2013; 8: e76160. doi: 10.1371/journal.pone.0076160 PMID: 24116093

23. Nakashashi-Oda C, Tahara-Hanaoka S, Shoji M, Okoshi Y, Nakano-Yokomizo T, Ohkochni N, et al. Apoptotic cells suppress mast cell inflammatory responses via the CD300a immunoreceptor. J Exp Med. 2012; 209: 1493–1503. doi: 10.1084/jem.20120096 PMID: 22826299

24. Izawa K, Yamashini Y, Maehara A, Takahashi M, Isobe M, Ito S, et al. The Receptor LMR3 Negatively Regulates Mast Cell Activation and Allergic Responses by Binding to Extracellular Ceramide. Immunity. 2012; 37: 827–839. doi: 10.1016/j.immuni.2012.08.018 PMID: 23123064

25. Yotsumoto K, Okoshi Y, Shibuya K, Yamazaki S, Tahara-Hanaoka S, Honda S-I, et al. Paired activating and inhibitory immunoglobulin-like receptors, MAIR-I and MAIR-II, regulate mast cell and macrophage activation. J Exp Med. 2003; 198: 223–233. doi: 10.1084/jem.20021825 PMID: 12874256

26. Cheng LE, Hartmann K, Roers A, Krummel MF, Locksley RM. Perivascular mast cells dynamically probe cutaneous blood vessels to capture immunoglobulin E. Immunity. 2013; 38: 166–175. doi: 10.1016/j.immuni.2012.09.022 PMID: 23290520

27. Hurst SD, Cooper CJ, Sutherland SM, Choi J, Jump RL, Levine AD, et al. The differentiated state of intestinal lamina propria CD4+ T cells results in altered cytokine production, activation threshold, and costimulatory requirements. J Immunol. 1999; 163: 5937. doi: 10.4049/jimmunol.163.12.5937

28. Hiroyama T, Miharada K, Sudo K, Danjo I, Aoki N, Nakamura Y. Establishment of mouse embryonic stem cell-derived erythroid progenitor cell lines able to produce functional red blood cells. PLoS One. 2010; 5: e1003. doi: 10.1371/journal.pone.0001544 PMID: 18253492

29. Marchler-Bauer A, Derbyshire MK, Gonzales NR, Lu S, Chitsaz F, Geer LY, et al. CDD: NCBI conserved domain database. Nucleic Acids Res. 2015; 43: D222–D226. doi: 10.1093/nar/gku1221 PMID: 25414356

30. Chen C-C, Grimbaldston MA, Tsai M, Weissman IL, Galli SJ. Identification of mast cell progenitors in adult mice. Proc Natl Acad Sci U S A. 2005; 102: 11408–11413. doi: 10.1073/pnas.0504197102 PMID: 16006518

31. Kitamura T, Koshino Y, Shibata F, Oki T, Nakajima H, Nosaka T, et al. Retrovirus-mediated gene transfer and expression cloning: Powerful tools in functional genomics. Exp Hematol. 2003; 31: 1544. doi: 10.1016/j.exphem.2003.07.005 PMID: 14585362

32. Saito H, Kato A, Matsumoto K, Okayama Y. Culture of human mast cells from peripheral blood progenitors. Nat Protoc. 2006; 1: 2178–2183. doi: 10.1038/nprot.2006.344 PMID: 17487210

33. Gurish MF, Ghildyal N, McNeil HP, Austen KF, Gillis S, Stevens RL. Differential expression of secretory granule proteases in mouse mast cells exposed to interleukin 3 and c-kit ligand. J Exp Med. 1992; 175: 1003–1012. doi: 10.1084/jem.175.4.1003 PMID: 1372640

34. Taketomi Y, Ueno N, Kojima T, Sato H, Murase R, Yamamoto K, et al. Mast cell maturation is driven via a group II phospholipase A2-prostaglandin D2-DP1 receptor paracrine axis. Nat Immunol. 2013; 14: 554–563. doi: 10.1038/ni.2586 PMID: 23624557
35. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996; 87: 1161–1169. doi:10.1016/S0092-8674(00)81812-7 PMID: 8980223

36. Takakura N, Huang XL, Naruse T, Hamaguchi I, Dumont DJ, Yancopoulos GD, et al. Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. Immunity. 1998; 9: 677–686. doi:10.1016/S1074-7613(00)80665-2 PMID: 9846489

37. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 2004; 118: 149–161. doi: 10.1016/j.cell.2004.07.004 PMID: 15260986

38. Lee O-H, Xu J, Fueyo J, Fuller GN, Aldape KD, Alonso MM, et al. Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin beta1-dependent adhesion to the extracellular matrix. Mol Cancer Res. 2006; 4: 915–926. doi:10.1158/1541-7786.MCR-06-0184 PMID: 17189382

39. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 2009; 10: 165–177. doi:10.1038/nrm2639 PMID: 19234476

40. De Palma M, Venneri MA, Galli R, Sergi LS, Politi LS, Sampaiolesi M, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 2005; 8: 211–226. doi:10.1016/j.ccr.2005.07.004 PMID: 15260986

41. Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, et al. Identification of proangiogenic Tie2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood. 2007; 109: 5276–5285. doi:10.1182/blood-2006-10-053504 PMID: 17327411

42. Koh GY. Orchestral actions of angiopoietin-1 in vascular regeneration. Trends Mol Med. 2013; 19: 31–39. doi:10.1016/j.molmed.2012.10.010 PMID: 23162855

43. Makinde TO, Arogawal DK. Increased expression of angiopoietins and Tie2 in the lungs of chronic asthmatic mice. Am J Respir Cell Mol Biol. 2011; 44: 384–393. doi:10.1165/rcmb.2009-0330OC PMID: 20463289

44. Moon KY, Lee PH, Park SW, Park CS, Jang AS. Serum angiopoietin is associated with lung function in patients with asthma: a retrospective cohort study. BMC Pulm Med. 2014; 14: 143. doi:10.1186/1471-2466-14-143 PMID: 25178399

45. Köksal BT, Ozbek OY, Bayraktar N, Yazici AC. Evaluation of angiopoietin 1 and 2, vascular endothelial growth factor, and tumor necrosis factor alpha levels in asthmatic children. Allergy Asthma Proc. 2014; 35: 482–488. doi:10.2500/aap.2014.35.3793 PMID: 25584916

46. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegradt SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997; 277: 55–60. PMID: 9204896

47. Kim I, Kim JH, Moon SO, Kwak HJ, Kim NG, Koh GY. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Oncogene. 2000; 19: 4549–4552. doi:10.1038/sj.onc.1203800 PMID: 11002428

48. Harfouche R, Hussain SNA. Signaling and regulation of endothelial cell survival by angiopoietin-2. Am J Physiol Heart Circ Physiol. 2006; 291: H1635–H1645. doi:10.1152/ajpheart.01318.2005 PMID: 16714355

49. Takakura N, Watanabe T, Suenobu S, Yamada Y, Noda T, Ito Y, et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell. 2000; 102: 199–209. PMID: 10943840

50. Zhou BO, Ding L, Morrison SJ. Hematopoietic stem and progenitor cells regulate the regeneration of their niche by secreting Angiopoietin-1. Elife. 2015; 4: e05521. doi: 10.7554/eLife.05521 PMID: 25821987

51. Lenter M, Uhlig H, Hamann A, Jenö P, Imhof B, Vestweber D. A monoclonal antibody against an activation epitope on mouse integrin chain beta 1 blocks adhesion of lymphocytes to the endothelial integrin alpha 6 beta 1. Proc Natl Acad Sci U S A. 1993; 90: 9051–9055. PMID: 7692444

52. Pepinsky RB, Mumford RA, Chen LL, Leone D, Amo SE, Riper G Van, et al. Comparative assessment of the ligand and metal ion binding properties of integrins alpha9beta1 and alpha4beta1. Biochemistry. 2002; 41: 7125–7141. PMID: 12033947

53. Yamakawa D, Kidoya H, Sakimoto S, Jia W, Naito H, Takakura N. Ligand-independent Tie2 dimers mediate kinase activity stimulated by high dose angiopoietin-1. J Biol Chem. 2013; 288: 12469–12477. doi:10.1074/jbc.M112.433979 PMID: 23504320
54. Lévesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood. 2001; 98: 1289–1297. PMID:11520773

55. Lévesque JP, Helwani FM, Winkler IG. The endosteal “osteoblastic” niche and its role in hematopoietic stem cell homing and mobilization. Leukemia. 2010; 24: 1979–1992. doi:10.1038/leu.2010.214 PMID:20861913

56. Ratajczak MZ, Adamik M. Membrane lipid rafts, master regulators of hematopoietic stem cell retention in bone marrow and their trafficking. Leukemia. 2015; 29: 1452–1457. doi: 10.1038/leu.2015.66 PMID:25748684